Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia

Abstract This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Binglei Zhang, Lingyun Chen, Jian Zhou, Yingling Zu, Ruirui Gui, Zhen Li, Juan Wang, Fengkuan Yu, Yanli Zhang, Huifang Zhao, Zhenyu Ji, Yongping Song
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5eb65bd70e574ceb9712c6801b7e4352
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5eb65bd70e574ceb9712c6801b7e4352
record_format	dspace
spelling	oai:doaj.org-article:5eb65bd70e574ceb9712c6801b7e43522021-12-02T13:39:34ZRuxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia10.1038/s41598-021-88080-32045-2322https://doaj.org/article/5eb65bd70e574ceb9712c6801b7e43522021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88080-3https://doaj.org/toc/2045-2322Abstract This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated.Binglei ZhangLingyun ChenJian ZhouYingling ZuRuirui GuiZhen LiJuan WangFengkuan YuYanli ZhangHuifang ZhaoZhenyu JiYongping SongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Binglei Zhang Lingyun Chen Jian Zhou Yingling Zu Ruirui Gui Zhen Li Juan Wang Fengkuan Yu Yanli Zhang Huifang Zhao Zhenyu Ji Yongping Song Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
description	Abstract This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated.
format	article
author	Binglei Zhang Lingyun Chen Jian Zhou Yingling Zu Ruirui Gui Zhen Li Juan Wang Fengkuan Yu Yanli Zhang Huifang Zhao Zhenyu Ji Yongping Song
author_facet	Binglei Zhang Lingyun Chen Jian Zhou Yingling Zu Ruirui Gui Zhen Li Juan Wang Fengkuan Yu Yanli Zhang Huifang Zhao Zhenyu Ji Yongping Song
author_sort	Binglei Zhang
title	Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_short	Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_full	Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_fullStr	Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_full_unstemmed	Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
title_sort	ruxolitinib early administration reduces acute gvhd after alternative donor hematopoietic stem cell transplantation in acute leukemia
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5eb65bd70e574ceb9712c6801b7e4352
work_keys_str_mv	AT bingleizhang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT lingyunchen ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT jianzhou ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yinglingzu ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT ruiruigui ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhenli ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT juanwang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT fengkuanyu ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yanlizhang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT huifangzhao ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhenyuji ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yongpingsong ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia
_version_	1718392617373270016

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia

Ejemplares similares